Loading clinical trials...

Substance Misuse To Psychiatric Disorders for Cannabis | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

Substance Misuse To Psychiatric Disorders for Cannabis

Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study

NCT03485274•The University of Hong Kong

View on ClinicalTrials.gov

Summary

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Eligibility

Age

16 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cannabis use disorder with anxiety or depressive symptoms or disorders; or positive cannabis test results in 1 month with anxiety or depressive symptoms

Exclusion Criteria

•Age \<16 years old
•Unable to read English or Chinese
•Unable to give informed consent
•Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation
•Had history of primary psychotic episode
•Had been diagnosed to have substance-induced mood disorder, other than cannabis
•Had been diagnosed to have mood disorders or anxiety disorders
•Had been taking maintenance therapeutic dose of antidepressant continuously \>= 6 months AND with depressive symptom or anxiety symptom being in remission
•Had known hypersensitivity to vortioxetine
•Had known history of serotonin syndrome
+4 more criteria

Locations (1)

Queen Mary Hospital

Hong Kong, Hong Kong

Key Dates

Start Date

July 25, 2018

Primary Completion Date

February 28, 2023

Completion Date

April 30, 2023

Last Updated

July 5, 2023

Enrollment

ACTUAL participants

Conditions

Cannabis Use DisorderDepressive StateAnxiety StateDepressionAnxiety DisordersPharmacotherapy

Interventions

Vortioxetine

DRUG

Treatment as Usual

OTHER

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

NCT05855668

Alcohol Use DisorderCannabis Use Disorder

View study

RECRUITINGNA

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

NCT06878859

Depression - Major Depressive DisorderCannabis Use Disorder+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 5, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Substance Misuse To Psychiatric Disorders for Cannabis

Inclusion Criteria

Exclusion Criteria

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative

Cannabinoids and Biological Reactivity to Stress

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

Perioperative Anxiety Risk Factors in Parents of Children Undergoing Thoracic Surgery